Low-dose dasatinib: when less can be more

Affiliations

Comment

Philip Crawford Amrein. Lancet Haematol. 2021 Dec.

. 2021 Dec;8(12):e867-e868.

doi: 10.1016/S2352-3026(21)00342-2.

¹ Massachusetts General Hospital, Boston, MA, USA. Electronic address: pamrein@partners.org.

No abstract available

Conflict of interest statement

I declare no competing interests.

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD. Soumerai JD, et al. Lancet Haematol. 2021 Dec;8(12):e879-e890. doi: 10.1016/S2352-3026(21)00307-0. Lancet Haematol. 2021. PMID: 34826411 Free PMC article. Clinical Trial.